# Cagrilintide > Source: https://chooseunscripted.com/peptide/cagrilintide/ > Content type: Peptide research profile > Last updated: September 4, 2026 **For research use only. Not for human or veterinary use.** ## Multi-Compound Blend No ## Product URL ## Scientific / Common Name Cagrilintide ## Alternative Names / Synonyms AM833 · AM-833 · NN0174-0833 ## Molecular Formula C₁₉₄H₃₁₂N₅₄O₅₉S₂ ## Molecular Weight 4,409 g/mol ## CAS Number 1415456-99-3 ## Clinical Development Phase Phase 3 ## Regulatory Status Investigational; not FDA approved. ## Peptide Classification Long-Acting Amylin Analog / Dual Amylin and Calcitonin Receptor Agonist (DACRA) ## Primary Research Focus Amylin receptor signaling; satiety regulation; body-weight regulation; energy intake; glucose metabolism; gastric emptying; metabolic signaling ## Mechanism Summary Cagrilintide is a **long-acting amylin analog that activates amylin and calcitonin-family receptors**. Amylin receptor signaling is involved in satiety, food-intake regulation, gastric emptying, and glucose-related metabolic signaling. Amylin receptors are complexes formed from the calcitonin receptor and receptor activity-modifying proteins. Structural research published in 2025 demonstrated cagrilintide binding and activation at **AMY1, AMY2, AMY3 and calcitonin receptors**, supporting its classification as a dual amylin/calcitonin receptor agonist. ## Evidence Summary Cagrilintide has progressed from early clinical studies into **Phase 3 development**. In a randomized Phase 2 study involving 706 participants assigned to cagrilintide, multiple cagrilintide groups produced greater mean body-weight reductions than placebo over 26 weeks. The highest studied group in that trial showed a 10.8% mean reduction compared with 3.0% with placebo under the trial-product estimand. Cagrilintide was subsequently evaluated as a monotherapy arm within the Phase 3 REDEFINE 1 program. A 2025 analysis reported a mean body-weight reduction of **11.8% versus 2.3% with placebo after 68 weeks** under the estimand assuming treatment adherence. These findings led Novo Nordisk to advance standalone cagrilintide into the dedicated **RENEW Phase 3 program**. Cagrilintide is also being studied in combination with the GLP-1 receptor agonist semaglutide as **CagriSema**. Results involving CagriSema should be distinguished from cagrilintide monotherapy because the combination activates two separate hormonal signaling pathways. ## Key References - Lau DCW, et al. [*Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.*](https://pubmed.ncbi.nlm.nih.gov/34798060/?utm_source=chatgpt.com) **The Lancet.** 2021. - Garvey WT, et al. [*Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.*](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081?utm_source=chatgpt.com) **New England Journal of Medicine.** 2025. - Cao J, et al. [*Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.*](https://pubmed.ncbi.nlm.nih.gov/40204768/?utm_source=chatgpt.com) **Nature Communications.** 2025. - Gu Y-M, et al. [*Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.*](https://pubmed.ncbi.nlm.nih.gov/40847076/?utm_source=chatgpt.com) **Acta Pharmacologica Sinica.** 2026. ## Last Scientifically Reviewed August 27, 2026 ## Quick Definition Cagrilintide is an investigational long-acting amylin analog that activates amylin and calcitonin receptors. It is currently in Phase 3 clinical development, with research focused primarily on satiety, metabolic regulation, and body-weight regulation. ## Targets / Receptors Amylin receptor signaling; calcitonin receptor activation; satiety regulation; appetite control; gastric emptying; energy intake; body-weight regulation; glucose metabolism ## Safety & Limitations Cagrilintide remains **investigational**, so its full long-term safety profile and benefit-risk profile have not yet been established through regulatory approval. In the Phase 2 study, the most frequently reported adverse events were gastrointestinal, particularly **nausea, constipation, and diarrhea**, along with administration-site reactions. Phase 3 cagrilintide data have also reported gastrointestinal adverse events including nausea, vomiting, diarrhea, and constipation, generally described in the trial population as primarily transient and mild to moderate. However, ongoing Phase 3 studies are specifically intended to provide additional evidence regarding efficacy and safety. Evidence from **CagriSema should not automatically be attributed to cagrilintide alone**, since semaglutide contributes GLP-1 receptor activity that cagrilintide itself does not possess. ## Frequently Asked Questions - ### What is cagrilintide? Cagrilintide is an investigational long-acting analog of amylin, a pancreatic hormone involved in satiety and metabolic regulation. It activates amylin receptors as well as the calcitonin receptor. - ### What receptors does cagrilintide target? Cagrilintide activates AMY1, AMY2, and AMY3 amylin receptors as well as the calcitonin receptor (CTR). This receptor activity has led to its classification as a dual amylin and calcitonin receptor agonist. - ### What is cagrilintide being researched for? Clinical research has focused primarily on body-weight regulation, satiety, energy intake, and metabolic effects in people with overweight or obesity. Dedicated Phase 3 trials are currently evaluating cagrilintide as a standalone investigational compound. - ### Is cagrilintide the same as CagriSema? No. Cagrilintide is one component of CagriSema. CagriSema combines cagrilintide, an amylin/calcitonin receptor agonist, with semaglutide, a GLP-1 receptor agonist. - ### Is cagrilintide FDA approved? No. Cagrilintide is currently investigational and is in Phase 3 clinical development. The cagrilintide-containing combination CagriSema has been submitted to the FDA for weight management, but that submission does not constitute approval of cagrilintide as a standalone drug. ## Available Research Compound - [Product page](https://chooseunscripted.com/shop/cagrilintide/index.md)